The present invention provides very high affinity antibodies, or
antigen-binding fragments thereof, that neutralize mature human
TGF-.beta.1, TGF-.beta.2, and TGF-.beta.3. The antibodies of the
invention are useful for treating cell proliferative disorders in a
mammal.